[{"orgOrder":0,"company":"City Therapeutics","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"City Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.48999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"City Therapeutics \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"4","companyTruncated":"City Therapeutics \/ Bausch & Lomb Incorporated"}]

Find Clinical Drug Pipeline Developments & Deals by City Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The collaboration aims on the development of a novel RNAi-based therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          January 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Bausch & Lomb Incorporated

                          Deal Size : $485.0 million

                          Deal Type : Collaboration

                          blank